Literature DB >> 15920901

In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.

S Sulochana1, F Rahman, C N Paramasivan.   

Abstract

The in vitro activity of fluoroquinolones, including lomefloxacin, ofloxacin, ciprofloxacin, sparfloxacin, moxifloxacin and gatifloxacin, was evaluated against 55 clinical isolates of Mycobacterium tuberculosis by absolute concentration method on Lowenstein-Jensen (L-J) and Middlebrook's 7H11 media. Both ofloxacin susceptible and ofloxacin resistant strains of M. tuberculosis isolates were tested. The in vitro activities of these fluoroquinolones on the M. tuberculosis isolates were in the order: lomefloxacin < ciprofloxacin < or = ofloxacin < sparfloxacin < moxifloxacin = gatifloxacin. Gatifloxacin and moxifloxacin showed low minimal inhibitory concentrations (MIC) for both ofloxacin resistant and ofloxacin susceptible strains even though some cross resistances were observed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15920901     DOI: 10.1179/joc.2005.17.2.169

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  17 in total

Review 1.  Surgery and pleuro-pulmonary tuberculosis: a scientific literature review.

Authors:  Dragan Subotic; Piotr Yablonskiy; Giorgia Sulis; Ioan Cordos; Danail Petrov; Rosella Centis; Lia D'Ambrosio; Giovanni Sotgiu; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

2.  Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment.

Authors:  M R Farhat; C D Mitnick; M F Franke; D Kaur; A Sloutsky; M Murray; K R Jacobson
Journal:  Int J Tuberc Lung Dis       Date:  2015-03       Impact factor: 2.373

3.  Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.

Authors:  Hana M El Sahly; Larry D Teeter; Kenneth C Jost; Denise Dunbar; Justin Lew; Edward A Graviss
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

4.  Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74.

Authors:  Ricky W T Lau; Pak-Leung Ho; Richard Y T Kao; Wing-Wai Yew; Terrence C K Lau; Vincent C C Cheng; Kwok-Yung Yuen; Stephen K W Tsui; Xinchun Chen; Wing-Cheong Yam
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

5.  New anti-tuberculosis agents amongst known drugs.

Authors:  Kathryn E A Lougheed; Debra L Taylor; Simon A Osborne; Justin S Bryans; Roger S Buxton
Journal:  Tuberculosis (Edinb)       Date:  2009-08-20       Impact factor: 3.131

Review 6.  Advances in the diagnosis and treatment of tuberculosis.

Authors:  Payam Nahid; Madhukar Pai; Philip C Hopewell
Journal:  Proc Am Thorac Soc       Date:  2006

7.  Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.

Authors:  Andrea Von Groll; Anandi Martin; Pontus Jureen; Sven Hoffner; Peter Vandamme; Françoise Portaels; Juan Carlos Palomino; Pedro Almeida da Silva
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

8.  Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis.

Authors:  Nele Coeck; Bouke C de Jong; Maren Diels; Pim de Rijk; Elisa Ardizzoni; Armand Van Deun; Leen Rigouts
Journal:  J Antimicrob Chemother       Date:  2016-02-06       Impact factor: 5.790

Review 9.  Combating Tuberculosis Infection: A Forbidding Challenge.

Authors:  Tejal Rawal; Shital Butani
Journal:  Indian J Pharm Sci       Date:  2016 Jan-Feb       Impact factor: 0.975

10.  Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.

Authors:  Mohideen S Jawahar; Vaithilingam V Banurekha; Chinnampedu N Paramasivan; Fathima Rahman; Rajeswari Ramachandran; Perumal Venkatesan; Rani Balasubramanian; Nagamiah Selvakumar; Chinnaiyan Ponnuraja; Allaudeen S Iliayas; Navaneethapandian P Gangadevi; Balambal Raman; Dhanaraj Baskaran; Santhanakrishnan R Kumar; Marimuthu M Kumar; Victor Mohan; Sudha Ganapathy; Vanaja Kumar; Geetha Shanmugam; Niruparani Charles; Murugesan R Sakthivel; Kannivelu Jagannath; Chockalingam Chandrasekar; Ramavaram T Parthasarathy; Paranji R Narayanan
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.